Xerostomia Therapeutics Market To Reach $2.70 Billion By 2030

Xerostomia Therapeutics Market Growth & Trends

The global xerostomia therapeutics market size is expected to reach USD 2.70 billion by 2030, expanding at a CAGR of 3.8% from 2023 to 2030, according to a new report by Grand View Research, Inc. Increase in favorable reimbursement policies for xerostomia products and growing awareness about associated diseases are the major factors contributing toward market growth.

In addition, increasing prevalence of xerostomia and associated diseases such as Sjogren’s syndrome, diabetes, hypertension, and Parkinson’s disease has a positive impact on the overall market. According to Colgate-Palmolive Company, 25 million people in the U.S. experience dry mouth. According to Sjogren Syndrome Foundation of America, around 4 million Americans are suffering from Sjogren’s syndrome, an autoimmune disorder.

Growing initiatives for raising awareness about xerostomia and associated diseases are expected to drive growth. For instance, Sjogren Syndrome Foundation of America conducts awareness programs and supports patients suffering from the syndrome in the U.S. and Canada. In 2012, the foundation launched the “5-Year Breakthrough Goal” with an aim to reduce the time required to diagnose the condition to less than 2.5 years by 2017.

Furthermore, major players focus on acquiring emerging companies and conduct programs to raise awareness about dry mouth condition. For instance, Orajel, a brand of Church & Dwight Co., Inc. initiated a campaign with the help of iCrossing, a digital marketing agency to educate parents about the importance of oral care.

 Request a free sample copy or view report summary: Xerostomia Therapeutics Market Report

Xerostomia Therapeutics Market Report Highlights

• The global xerostomia therapeutics market size was estimated at USD 2.0 billion in 2022 and is expected to grow with CAGR of 3.8% from 2023 to 2030

• The OTC segment dominated the market due to factors such as ease in availability, affordability, and higher efficiency

• The dentifrices segment is expected to grow at the fastest CAGR over the forecast period.

• North America held the largest share in 2022 owing to factors such as increasing prevalence of diseases resulting in dry mouth and growing initiatives for raising awareness about xerostomia

• The Asia Pacific region is anticipated to witness lucrative growth over the next decade due to increasing awareness of the disease and growing healthcare expenditure

• Some of the key players such as GlaxoSmithKline plc; Church & Dwight Co., Inc.; and Colgate-Palmolive Company dominated the global xerostomia therapeutics market

Xerostomia Therapeutics Market Segmentation

Grand View Research has segmented the global xerostomia therapeutics market based on product, type, and region:

Xerostomia Therapeutics Type Outlook (Revenue, USD Million, 2018 - 2030)

• OTC

• Prescription

Xerostomia Therapeutics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Salivary Stimulants

• Salivary Substitutes

• Dentifrices

Xerostomia Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Xerostomia Therapeutics Market

• GlaxoSmithKline plc

• Church & Dwight Co., Inc.

• Colgate-Palmolive Company

• Hikma Pharmaceuticals PLC

• Pendopharm

• Sun Pharmaceuticals Industries Ltd.

• Lupin Pharmaceuticals, Inc.

• Pfizer, Inc.

• Parnell Pharmaceuticals, Inc.

• Acacia Pharma

• OraCoat